Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

Medigene AG. (5/24/17). "Press Release: Reports Outcome of Annual General Meeting and Announces New Supervisory Board Members". Planegg.

Organisations Organisation Medigene AG (FSE: MDG1, Prime Standard)
  Group Medigene (Group)
  Organisation 2 Basilea Pharmaceutica International Ltd.
  Group Basilea (Group)
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 T cell therapy
Persons Person Manchester, Keith (QVT 201705 Managing Director + Head Life Sciences QVT Financial LP)
  Person 2 Zettlmeissl, Gerd (Intercell 2005–201105 CEO before COO since 2001 before Chiron Behring before Behringwerke)

- Shareholders approve all resolutions with a high majority

- Dr. Keith Manchester, Ronald Scott and Dr. Gerd Zettlmeissl elected as new members for extended Supervisory Board

Medigene AG (MDG1, Frankfurt, Prime Standard, TecDAX) announces that the shareholders of the company approved all resolutions with large majorities during the Annual General Meeting today.

Three new members were elected in a supplemental election to Medigene's Supervisory Board which now increased to six members: Dr. Keith Manchester, Managing Director and Head at Life Sciences QVT Financial LP, USA; Ronald Scott, Chief Executive Officer of Basilea Pharmaceutical International Ltd., Switzerland; and Dr. Gerd Zettlmeissl, self-employed consultant immunophrophylaxis/-therapy, Austria.

Prof. Horst Domdey, Chaiman of the Supervisory Board, commented: "We are delighted that Medigene was able to attract three new highly qualified personalities with excellent industry expertise for Medigene's Supervisory Board. We would like to warmly welcome them and look forward to our future cooperation."

Prof. Dolores Schendel, CEO and CSO of Medigene AG, adds: "The newly elected members of the Supervisory Board will support Medigene to further develop a leading role in the innovative field of immunotherapies with their significant experience in the development and commercialization of biopharmaceutical therapies and their outstanding knowledge of the pharma and capital markets. On behalf of the Board I thank the shareholders of Medigene AG for their vote of confidence."

The approval rates of the Annual General Meeting for proposed resolutions were between 90.6 and 99.9%.

For more information, please follow the link:

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Record changed: 2023-06-05


Picture EBD Group BIO-Europe 2023 Munich BEU23 650x200px

More documents for Medigene (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x300px

» top